皮质类固醇加入局麻药用于慢性非癌痛注射:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入73项英文随机对照试验,评估局麻药中加入类固醇对慢性非癌痛注射的获益与安全性。结果显示虽提高成功率(RR=1.14),但去除两项鞘内注射研究后效应减半,疼痛评分差异无临床意义,其他结局与不良事件无差异。结论为获益微小且潜在危害,可考虑单用局麻药并共同决策。
要点
- 局麻药加类固醇提高成功率RR=1.14,但去除两项鞘内研究后NNT由13降至22。
- 疼痛评分差异MD=0.44单位,无临床意义。
- 其他结局与不良事件无差异,避免高剂量和系列注射。
核心结论
- 局麻药中加入皮质类固醇获益微小且潜在危害,单用局麻药可能具有治疗作用。
- 应基于患者偏好共同决策,若使用需避免高剂量和系列注射。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE和CENTRAL从建库至2019年5月。
- 纳入73项英文随机对照试验,共5097篇摘要筛选,双人重复筛选与提取。
- 主要结局为疼痛改善,采用随机效应模型,报告相对风险或均数差及95%置信区间。
主要发现
- 42项试验3592例患者显示成功率提高RR=1.14(95%CI 1.03-1.25),NNT=13。
- 去除两项鞘内注射研究后效应量下降近50%,NNT=22。
- 54项试验4416例患者疼痛评分差异MD=0.44单位(95%CI 0.24-0.65),无临床意义。
- 其他结局和不良事件无差异,基于临床类别的亚组效应未检测到。
- Meta回归显示类固醇剂量或随访时长与疼痛缓解无显著关联。
关键数值与推荐
- 成功率RR=1.14(95%CI 1.03-1.25),NNT=13。
- 疼痛评分MD=0.44单位(95%CI 0.24-0.65)。
- 去除两项鞘内注射研究后NNT=22。
临床怎么用
- 可考虑单用局麻药注射,不仅用于诊断也可能有治疗作用。
- 与患者共同决策是否加用类固醇,若使用避免高剂量和系列注射。
局限性
- 去除两项鞘内注射研究后效应量下降近50%,提示结果稳健性有限。
- 疼痛评分差异无临床意义,其他结局无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite common use, the benefit of adding steroids to local anaesthetics (SLA) for chronic non-cancer pain (CNCP) injections is uncertain. We performed a systematic review and meta-analysis of English-language RCTs to assess the benefit and safety of adding steroids to local anaesthetics (LA) for CNCP. METHODS: We searched MEDLINE, EMBASE, and CENTRAL databases from inception to May 2019. Trial selection and data extraction were performed in duplicate. Outcomes were guided by the Initiative in Methods, Measurements, and Pain Assessment in Clinical Trials (IMMPACT) statement with pain improvement as the primary outcome and pooled using random effects model and reported as relative risks (RR) or mean differences (MD) with 95% confidence intervals (CIs). RESULTS: Among 5097 abstracts, 73 trials were eligible. Although SLA increased the rate of success (42 trials, 3592 patients; RR=1.14; 95% CI, 1.03-1.25; number needed to treat [NNT], 13), the effect size decreased by nearly 50% (NNT, 22) with the removal of two intrathecal injection studies. The differences in pain scores with SLA were not clinically meaningful (54 trials, 4416 patients, MD=0.44 units; 95% CI, 0.24-0.65). No differences were observed in other outcomes or adverse events. No subgroup effects were detected based on clinical categories. Meta-regression showed no significant association with steroid dose or length of follow-up and pain relief. CONCLUSIONS: Addition of cortico steroids to local anaesthetic has only small benefits and a potential for harm. Injection of local anaesthetic alone could be therapeutic, beyond being diagnostic. A shared decision based on patient preferences should be considered. If used, one must avoid high doses and series of steroid injections. CLINICAL TRIAL REGISTRATION: PROSPERO #: CRD42015020614.
引用
- Shanthanna H, Busse J, Wang L, et al. Addition of corticosteroids to local anaesthetics for chronic non-cancer pain injections: a systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2020. PMID: 32798067. doi:10.1016/j.bja.2020.06.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。